Clinical Trial Update: FASENRA Regulatory Postmarketing Surveillance in Korea

View source ↗

Summary

Postmarketing surveillance in Korea assessing safety of FASENRA (benralizumab) for asthma and eosinophilic granulomatosis with polyangiitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• FASENRA (BENRALIZUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma, EGPA(Eosinophilic Granulomatosis With Polyangiitis) | Status: COMPLETED